Skip to main content

Mahoney Michael F's Form 4 filing

Boston Scientific Corp (BSX) · filed May 5, 2025

Accession no.
0001225208-25-004717
Filed
May 5, 2025
Trade date
May 1, 2025
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $16.9M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Mahoney Michael FCIK 0001533022Director, Officer (Chairman, President & CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 1, 2025Common StockMOption exerciseAcquired+56,212$17.26+$970,219.121,650,742Direct
May 1, 2025Common StockMOption exerciseAcquired+49,407$24.55+$1,212,941.851,700,149Direct
May 1, 2025Common StockSSaleDisposed−73,161$102.92F2−$7,529,730.121,626,988Direct
May 1, 2025Common StockSSaleDisposed−91,282$102.13F3−$9,322,630.661,535,706Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
May 1, 2025Common StockMOption exerciseDisposed−56,212$0.00$056,212Direct
May 1, 2025Common StockMOption exerciseDisposed−49,407$0.00$0197,628Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $102.64 to $103.34, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

F3

Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $101.61 to $102.60, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)